CURRICULUM VITAE

September, 2017

NAME: Bruce C. Corser, M.D., M.B.A **Signature:** 

CEO – Sleep Management Institute
CEO – Your MD
CEO – OSA Medical Products
CEO – Intrepid Research

OFFICE ADDRESSES:

Sleep Management Institute (sleep medicine practice headquarters)
8250 Kenwood Crossing Way, Suite 225
Cincinnati, OH 45236
Telephone (513) 721-7533
Fax: (513) 721-1036

Your MD (concierge internal medicine practice)
8250 Kenwood Crossing Way, Suite 225
Cincinnati, OH 45236
Telephone (513) 721-9600
Fax: (513) 721-1649

OSA Medical Products (medical equipment company)
7714 Montgomery Road, Suite L
Cincinnati, OH 45236
Telephone (513) 721-6088
Fax: (513) 721-6086

Intrepid Research (clinical research company)
4421 Eastgate Boulevard, Suite 200
Cincinnati, OH 45245
Telephone: (513) 977-8891
FAX: (513) 943-8150

E-mail: brucecorser1@gmail.com

BOARD CERTIFICATION(S):

1996 Sleep Disorders (active)
1989 Critical Care Medicine (inactive)
1988 Pulmonary Medicine (active)
1983 Internal Medicine (active)

LICENSURE:

Ohio:	35.046569
Kentucky:	30722
Indiana:	01061490A

EDUCATION:

1998 – 1999 Master of Business Administration Degree (with Honors)
Xavier University
Cincinnati, Ohio

1976 – 1980 Medical Degree (MD)
Upstate Medical Center
Syracuse, New York

1972 – 1976 Bachelor of Arts Degree (Cum Laude)
Division College
Davidson, North Carolina

PROFESSIONAL TRAINING:

1997 – 1999 Alliance Partners Quality Improvement Committee

1997 – 1999 United Health Care Credentialing Committee

1985 – 1986 Chief Medical Resident
University of Cincinnati
Cincinnati, Ohio

1984 – 1987 Fellowship – Pulmonary and Critical Care
University of Cincinnati
Cincinnati, Ohio

1980 – 1983 Residency – Internal Medicine
University of Cincinnati
Cincinnati, Ohio

PROFESSIONAL EXPERIENCE:

2014 – Pres. CEO – Intrepid Research
2003 – Pres. CEO – Your MD

1995 – 2014 Medical Director – Community Research, Cincinnati, OH

1995 – Pres. CEO – Sleep Management Institute

1994 – 1999 Medical Director – St Luke Hospital East/West Sleep Disorders Center, KY

1994 – 1999 Medical Director – Northern Kentucky Nursing Services, Florence, KY

1989 – 1995 Medical Director – Deaconess Center for Sleep Disorders, Deaconess Hospital, Cincinnati, OH

1987 – Pres. Private Practice Internal Medicine, Cincinnati, OH

1983 – 1984 Industrial Medicine and Doctor's Urgent Care Office, Cincinnati, OH

HOSPITAL AFFILIATIONS:

Christ Hospital, Cincinnati, OH
Mercy Hospital Kenwood, Cincinnati, OH
Dearborn county Hospital, Dearborn, IN

ORGANIZATIONS:

American College of Physicians
American Academy of Sleep Medicine
American Medical Association
Ohio State Medical Association
Cincinnati Society of Internal Medicine
American College of Chest Physicians

PUBLICATIONS:

Baughman, R., Mangel, D., Corser, B., 1987. Phospholipids in Surfactant Enhance Monocyte/Macrophage Tumor Cytoxicity. Chest 91, 285.

Baughman, R., Corser, B., Strohofer, S., Hendricks, D., 1986. Spontaneous Hydrogen Peroxide Release from Alveolar Macrophages of Some Cigarette Smokers. Journal of Laboratory and Clinical Medicine 107, 233.

Javaheri, S., Logeman, T., Corser, B., Guerra, L., Means, E., 1989. Diaphragmatic Paralysis. American Journal of Medicine 86, 623.

D Alan Lankford, Bruce C Corser, Yan-Ping Zheng, Zhengrong Li, Duane B Snavely, Christopher R Lines, Steve Deacon, 2008 Oct;31. Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies.
Sleep (10):1359-70.

Thomas Roth, David Mayleben, Bruce C Corser, Nikhilesh N Singh, 2008 Jan 23. Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol (1): 13-20.

Thomas Roth, Roberta Rogowski, Steven Hull, Howard Schwartz, Gail Koshorek, Bruce Corser, David Seiden, Alan Lankford, 2007 Nov 30. Efficacy and safety of doxepin 1mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep (11):1555-61.

Francis Burch, Richard Fishman, Nicholas Messina, Bruce Corser, Florin Radulescu, Adrian Sarbu, Marcela M Craciun-Nicodin, Rodica Chiriac, Andre Beaulieu, Jude Rodrigues, Philippe Beignot-Devalmont, Alain Duplan, Sybil Robertson, Louise Fortier, Sylvie Bouchard, 2007 Sep 21, Epub 2007 Jun 21. A comparison of the analgesic efficacy of Tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. J Pain Symptom Management 34(3):328-38.

Gary K. Zammit, Bruce Corser, Karl Doghramji, June M Fry, Steven James, Andrew Krystal, Richard M Mangano. 2006 Oct 2. Sleep and residual sedation after administration of zaleplon, zolpidem and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med; (4):417-23.

CLINICAL RESEARCH EXPERIENCE:

2017 Principal Investigator: A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients with Influenza

2017 Principal Investigator: A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Influenza Complications

2016 Principal Investigator: Protocol Number THN3, Targeted Hypoglossal Neurostimulation Study #3

2015 Principal Investigator: A Long-Term, Open-Label Safety and Maintenance of Efficacy Study of JZP-110 [(*R*)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep Apnea

2015 Principal Investigator: A 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the treatment of excessive sleepiness in subjects with narcolepsy

2015 Principal investigator: A 12-week, double-blind, placebo-controlled, randomized, parallel group, multicenter study of the safety and efficacy of [(R)-2-amino-3-phenylpropyl-carbamate hydrochloride] in the treatment of excessive sleepiness in subjects with obstructive sleep apnea

2013 Sub Investigator: A 12-week treatment, multi-center, randomized, double blind, parallel-group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate/glycopyrronium bromide) in COPD patients with moderate to severe airflow limitation

2012 Sub Investigator: Efficacy Study of Fluzone High-Dose Vaccine Compared with Fluzone Vaccine in Elderly Adults

2011 Sub Investigator: A Multicenter, Open Label, Safety Study of Diclofenac Nano-formulation Capsules in Subjects with Osteoarthritis of the Knee or Hip

2011 Sub Investigator: A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson's Disease

2011 Sub Investigator: The effect of 30 minute, light exposure for the treatment of Seasonal Affective Disorder

2011 Sub Investigator: The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant

2011 Sub Investigator: A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with major Depressive Disorder with residual Symptoms or Inadequate Response Following Treatment with an Antidepressant

2011 Sub Investigator: A Randomized, Double-Blind, Placebo-Controlled, 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients with Non-Cancer-Related Pain and Opiod-induced Constipation (OIC)

2011 Sub Investigator: A IIb Double-Blind, Randomized, Placebo-Controlled, Dose-ranging Trial of BMS- 927711 for the Acute Treatment of Migraine

2011 Sub Investigator: A Phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of BI 10773 25mg/linagliptin 5mg and BI 10773 1Omg linagliptin 5mg Fixed Dose Combination tablets compared with the individual components (BI 10773 25mg, BI 10773 10mg, and linagliptin 5mg) for 52 weeks in treatment naive and metformin treated patients with type 2 diabetes mellitus with insufficient glycaemic control

2011 Principal Investigator: A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubriprostone in Subjects with Opiod-induced Bowel Dysfunction

2011 Principal Investigator: A Phase IIb, Randomized, Double-blind, Two-Arm, Multi-Center, Placebo Controlled Study to Assess the Efficacy and Safety of EN3324 (Axomadol) in Subjects with Moderate to Severe Chronic Low Back Pain (CLBP)

2011 Sub Investigator: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled, Fixed Dose, Parallel Group, Efficacy and Safety Study of Diclofenac Nano-formulation Capsules in Subjects with Osteoarthritis of the Knee or Hip

2007 Sub Investigator: Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Analgesic Efficacy of Nalbuphine-ER in patients with Chronic Pain Secondary to Osteoarthritis of the Kneel/Hip

2007 Sub Investigator: Single center, Randomized, Placebo-Controlled, Four-Period Crossover Study to evaluate the Pharmacodynamic (PD) Effects of PD6735 (50 mg) and EtOH (0.6g/kg) interaction in Healthy Adults

2007 Sub Investigator: A Study to Assess the Effects of Zolpidem Tartrate Lozenges (INTERMEZZO 3.5 MG) on Psychomotor Performance and Memory when Administered Orally

2007 Sub Investigator: A Randomized, Placebo-Controlled, Double-Blind Study of Effects on Jet Lag

2007 Principal Investigator: A Study to Determine the Pharmacokinetics of A-2 Equol in Healthy Post- Menopausal Women

2007 Sub Investigator: A Double-Blind, Randomized, Placebo-Controlled Study Examining the Safety, Efficacy, and Tolerability of SEP-225289 in Subjects with Major Depressive Disorder (including Atypical and Melancholic Features)

2007 Sub Investigator: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co Administered with Amlodipine 5 mg in Subjects with Essential Hypertension

2007 Sub Investigator: A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 with Valsartan in Subjects with Essential Hypertension

2007 Sub Investigator: A Six Week, Double Blind, Multicenter, Placebo Controlled Study Evaluating the Efficacy and Safety of Flexible Dosed of Oral Ziprasidone and Add On, Adjunctive Therapy with Lithium, Valproate or Lamotrigine in Bipolar 1 Depression

2007 Principal Investigator: A double-blind, randomized, parallel group, placebo-controlled sleep laboratory efficacy and safety study with Org 50081 in elderly subjects with chronic primary insomnia

2007 Principal Investigator: A six-week, double-blind, randomized, placebo-controlled, parallel group, efficacy and safety, sleep lab trial with Org 50081 in patients with chronic primary insomnia

2007 Principal Investigator: Fifty-two weeks, open-label extension trial to evaluate safety and efficacy of Org 50081 in outpatients with chronic primary insomnia who completed Clinical Trial Protocol 176001 or 176002

2007 Principal Investigator: PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Placebo- Controlled, 5-Way Crossover, Multicenter Polysomnography Trial of PD 0200390 in Adults with Primary Insomnia

2007 Principal Investigator: Liraglutide Effect and Action in Diabetes -LEAD 6. Effect on glycemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. A 26-week randomized, open-label, active comparator, 2-armed, parallel-group, multi-center, multi-national trial with a 14-week non-randomized extension period

2007 Sub Investigator: An Exploratory Phase IIIb, Single-Blind, Outpatient Study to Assess Next-Day Functioning in Adult Primary Insomnia Patients Following the Administration of NBI-34060 Capsules During the Night

2007 Principa1 Investigator: Multi-center, parallel group, double-blind, placebo controlled, dose ranging study of the efficacy and tolerability of tonabersat in the prophylaxis of migraine headache and open label extension to evaluate the single dose and steady state pharmacokinetics of flibanserin in pre- menopausal women with hypoactive sexual desire disorder

2007 Sub Investigator: A 2 Week, Randomized, Double Blind, Placebo and Positive Controlled, Parallel Group, Multi-center Study to Assess the Efficacy and Tolerability Of PF-00592379 in Patients with Moderate to Severe Pain Due to Osteoarthritis

2007 Sub Investigator: A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50 to 59 Years of Age

2007 Principal Investigator: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate the Safety and Efficacy of MK-0249 in Treating Refractory Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea/Hypopnea Syndrome Appropriately Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy

2007 Principal Investigator: Establishing Content Validity of the Sleep and the Daytime Sleepiness Diaries via Cognitive Debriefing Interviews

2007 Sub Investigator: A Multi-center, Randomized, Double-Blind, "Crossover" Design Study to Evaluate the Lipid-Altering Efficacy of MK-0524B Combination Tablet Compared to NIK-0524A + Simvastatin Co-administration in Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

2007 Sub Investigator: A Multi-center, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus

2007 Principal Investigator: A Phase II Randomized, Double-blind, Double-dummy, Placebo and Comparator Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of a Single Dose of JNJ-17216498 Administered to Subjects with Narcolepsy

2007 Principal Investigator: Effect of the Consumption of a Fermented Dairy Product on Immune Parameters in Healthy Adults

2007 Sub Investigator: A Randomized, Multi-center, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Pain Caused by Mild to Moderate Osteoarthritis of the Knee

2007 Sub Investigator: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Trexima™ (Sumatriptan +Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine

2007 Principal Investigator: A 2-Week, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy (Throughout the Day) and Safety of Armodafinil (200 mg/day) as Treatment for Adults with Excessive Sleepiness Associated with Narcolepsy

2007 Sub Investigator: A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients with Generalized Anxiety Disorder

2007 Sub Investigator: Multicenter, double-blind, randomized, placebo-controlled, 5-period, 5-treatment crossover, dose-finding study to evaluate the efficacy and safety of oral administration of ACT-078573 in elderly subjects with chronic primary insomnia

2007 Sub Investigator: A Randomized, Double-blind, Placebo-controlled, and Parallel Group Study of the Efficacy and Safety of the Zolpidem Tartrate Lozenge in Adult Subjects with Insomnia Characterized by Difficulty Returning to Sleep after Awakening in the Middle-of-the-Night

2007 Sub Investigator: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, and Multicenter Study to Evaluate Treatment with SYR-472 in Subjects with Type 2 Diabetes

2007 Principal Investigator: A Phase I, open-label, parallel, and within-groups sequential trial to evaluate the single dose and steady state pharmacokinetics of flibanserin in pre-menopausal women with hypoactive sexual desire disorder

2007 Principal Investigator: A randomized, multi-center, double-blind, placebo-controlled, parallel group study to assess the hypnotic efficacy of EVT201 in the treatment of primary insomnia in elderly patients with daytime sleepiness

2007 Principal Investigator: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose- Ranging Study to Evaluate the Safety and Efficacy of HAE1 (PR098498) in Subjects with Moderate to Severe Allergic Asthma

2007 Sub Investigator: A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients with Major Depressive Disorder

2007 Sub Investigator: Semi-Structured Qualitative Interviews to Assess Patient Opinions and Experiences with Treatment for Non-Restorative Sleep

2007 Principal Investigator: A Multicenter, Randomized, Double blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20 MG/DAY AND SOMG/DAY) in the Treatment of Primary Insomnia

2006 Principal Investigator: A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects with Primary Chronic Insomnia

2006 Principal Investigator: A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as co-administered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in Patients with Mixed Hyperlipidemia

2006 Principal Investigator: A Randomized, Open-label, Two Period Crossover Study to Evaluate the Pharmacokinetics of ST Zolpidem in Healthy Elderly Subjects as Compared to Healthy Non-Elderly Adult Subjects

2006 Sub Investigator: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 in Patients with Restless Legs Syndrome

2006 Principal Investigator: A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Assess the Safety, Tolerance and Efficacy of a Single Subcutaneous Dose of Tezampanel in Patients with Acute Migraine

2006 Principal Investigator: A Long-Term, Open-Label Safety and Efficacy Study of Xyrem® (sodium oxybate) in Subjects with Fibromyalgia

2006 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia

2006 Principal Investigator: A 12 week, multi-center, double-blind, placebo-controlled, parallel group, flexible dose, polysomnography study of Ropinirole controlled release for Restless Leg Syndrome (RLS) in RLS patients with sleep disturbance and periodic limb movements

2006 Sub Investigator: An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 MG/DAY) in the adjunctive treatment of patients with generalized anxiety disorder (GAD) who have not optimally responded to existing therapies

2006 Sub Investigator: A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura

2006 Sub Investigator: A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long-Term Treatment of Acute Migraine with or Without Aura

2006 Principal Investigator: A Long-Tem, Open-Label, Safety Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Chronic Moderate to Severe Nonmalignant Pain

2006 Sub Investigator: An Open-Label, 52-Week Extension Study Assessing XP 13512 Safety and Efficacy in Patients with Restless Legs Syndrome

2006 Sub Investigator: A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin I 0 mg versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients with Hypercholesterolemia at High Risk for CHD

2006 Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee.

2006 Sub Investigator: A 4-Week Dose-Ranging Study to Evaluate Antidyslipidemic Effects, Other Pharmacodynamic Effects, Safety, and Tolerability of AZD6610 with Concomitant Open-Label Sinvastatin Therapy in Patients with Elevated Triglycerides, Elevated Low Density Lipid

Cholesterol and Abdominal Obesity: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study with Fenofibrate as Reference Treatment

2006 Sub Investigator: A Multicenter, double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel) Sustained-release as Monotherapy in Adult Patients with Acute Bipolar Depression

2006 Principal Investigator: Effect of Gender and Body Mass Index on the Accuracy of the LifeShirt™ System to Assess Cough in Patients with Chronic Bronchitis and Chronic Obstructive Pulmonary Disease

2006 Principal Investigator: A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of a single oral dose of VEC-162 (20, 50, and 100 mg) and matching placebo in healthy male and female subjects with induced transient insomnia

2006 Principal Investigator: A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Assess the Safety, Tolerance and Efficacy of a Single Subcutaneous Dose of Tezampanel in Patients with Acute Migraine

2006 Principal Investigator: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Proof-of-Concept Study to Evaluate the Safety and Efficacy of Ramelteon Taken in Combination with Doxepin for the Treatment of Subjects with Chronic Insomnia

2006 Sub Investigator: An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal Rotigotine in Subjects with Idiopathic Restless Legs Syndrome

2006 Sub Investigator: An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating the Efficacy, Safety and Tolerability of Two Fixed Doses (100 mg and 30 mg Once Daily) of Saredutant in Patients with Generalized Anxiety Disorder

2006 Sub Investigator: A multicenter, randomized, 24-52-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in the prevention of relapse of depressive symptoms in outpatients with major depressive disorder who achieved an initial response to 12 weeks of open-label treatment with saredutant 100 mg once daily

2006 Sub Investigator: A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin 250 mg and 500 mg in transient insomnia induced by a sleep phase advance

2006 Sub Investigator: An 8-week, randomized, double-blind, placebo-controlled, multicenter, and proof of concept trial of PD 0200390 in subjects with non-restorative sleep

2006 Sub Investigator: A Randomized, Double-blind, Placebo and active controlled, multicenter, proof of concept trial of PD 0200390 in subjects with non-restorative sleep

2006 Principal Investigator: A Multi-Center, Randomized, Double-blind, Placebo Controlled, Parallel Study of The Efficacy and Safety of immediate Release Tablets of 1 mg, 3 mg, 10 mg, and 20 mg of NG2-73 and Placebo for Sleep Initiation in A Model of Transient Insomnia in Healthy Adults

2006 Sub Investigator: A 2-Period Crossover Experimental Medicine Study of the Effects of MK-0928 Treatment Compared with Placebo on Daytime Performance in Elderly Patients with Primary Insomnia

2006 Primary Investigator: A Double-Blind, Placebo-Controlled, Randomized, Cross-Over Polysomnographic Study of MK-0928 15 mg in Adult Patients with Primary Insomnia

2006 Sub Investigator: A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima™ (sumatriptan, 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks

2006 Primary Investigator: A 28 day, Polysomnographic and Subjective Assessment of GW679769, 10 and 30 mg, for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo- Controlled Trial

2006 Sub Investigator: Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients

2006 Sub Investigator: Effectiveness and Safety of Frovatriptan for the Management (Acute Treatment) of Menstrual Migraine

2006 Principal Investigator: A Randomized, Double-Blind Comparison of 5 mg of LY2422347, 15 mg of LY2422347, and Placebo in the Treatment of Patients with Primary Insomnia

2006 Principal Investigator: A Multicenter, Randomized, Double-Blind, Parallel Group, Dose-Finding Trial to Evaluate the Safety and Efficacy of Fluticasone Propionate Combined with Formoterol Fumarate in Patients with Chronic Obstructive Pulmonary Disease

2006 Sub Investigator: A Multicenter, Double-blind Study on the Efficacy of Aripiprazole in Combination with Lamotrigine in the Long-term Maintenance Treatment of Patients with Bipolar I Disorder with a Recent Manic or Mixed Episode

2006 Sub Investigator: A randomized, double-blind, double-dummy, placebo-controlled, 3x4 factorial design trial to evaluate telmisartan 20, and 80 mg tablets in combination with ramipril 1.25, 10 and 20 mg capsules after eight weeks of treatment in patients with Stage I or II hypertension with an ABPM sub-study

2006 Principal Investigator: A phase IV randomized, double-blind, active and placebo-controlled, 6-week trial to investigate the efficacy and safety of a starting (and fixed) dose of 0.25 mg pramipexole (Mirapex®) in patients with idiopathic Restless Legs Syndrome

2006 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one-year) Efficacy and Safety of Tiotropium Inhalation Solution 5mg (2 puffs of 2.5mg) Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)

2006 Sub Investigator: A Multi-center, Double-blind, Randomized-Withdrawal, Parallel-group, Placebo- controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Monotherapy in the Maintenance Treatment of Patients with Generalized Anxiety Disorder Following an Open-Label Stabilization Period

2006 Sub Investigator: A randomized, double-blind, placebo controlled, 3-way cross-over study to evaluate effects of APD125 in patients with insomnia

2006 Sub Investigator: A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Dose Ranging Study of Erdosteine for the Treatment of Stable Chronic Bronchitis Associated with Chronic Obstructive Pulmonary Disease

2006 Principal Investigator: A Phase 3, Open-label Period followed by a Randomized, Double-blind, and Placebo controlled Study of the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicoden ® CR) Compared to Placebo in Subjects with Chronic Low Back Pain

2005 Principal Investigator: An Open Pilot Clinical Trial to Evaluate the Effect of Marplan® (Isocarboxazid) in Migraine Prophylaxis

2005 Sub Investigator: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients with Restless Legs Syndrome

2005 Sub Investigator: Effectiveness and Safety of Frovatriptan for the Management (Acute Treatment) of Menstrual Migraine

2005 Principal Investigator: Accuracy of the LifeShirtTM System to Assess Cough over a Period of 4-Hours in Patients with Chronic Obstructive Pulmonary Disease

2005 Principal Investigator: A 2-Period Crossover Experimental Medicine Study of the Effects of MK-0928 Treatment Compared with Placebo on Daytime Performance in Elderly Patients with Primary Insomnia

2005 Sub Investigator: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Proof-of-Concept Study to Evaluate the Safety and Efficacy of Rozerem taken in Combination with Gabapentin for the Treatment of Subjects with Chronic Insomnia

2005 Sub Investigator: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for Trexima (sumatriptan 8Smg/naproxen sodium 500Ing) Administered during the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks

2005 Sub Investigator: A 12-Week, Open-Label, Safety Trial of Pregabalin in Patients with Fibromyalgia

2005 Sub Investigator: A 14-Week, Randomized, Double-blind, Placebo-controlled Trial of Pregabalin Twice Daily in Patients with Fibromyalgia

2005 Principal Investigator: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study of the Effectiveness of Topiramate in Preventing Transformation from Episodic Migraine to Chronic Daily Headache in Adult Subjects

2005 Sub Investigator: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of Bicifadine 200 mg BID, Bicifadine 400 mg BID, and Bicifadine 400 mg TID in the Treatment of Chronic Low Back Pain

2005 Principal Investigator: A Randomized, Double-Blind Comparison of 5 mg of LY2422347, 15 mg of LY2422347, and Placebo in the Treatment of Patients with Primary Insomnia

2005 Sub Investigator: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of lndiplon Therapy Initiated with Sertraline Versus Sertraline Monotherapy in Subjects with Insomnia and Co-Existing Major Depressive Disorder

2005 Principal Investigator: An Open-Label Safety Study with Intermittent Use of HKT-500 In Subjects with Lower Back Pain, Pain from Osteoarthritis of the Knee, Shoulder Pain or Lateral Epicondylitis Pain

2005 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Long-Term Efficacy and Safety of Doxepin HCl in Primary Elderly Insomnia Patients with Sleep Maintenance Difficulties

2005 Principal Investigator: A Randomized, Double-Blind, Placebo and Positive-Controlled, Parallel-Group, Multicenter Study of Oral Doses of CJ-023, 423 Administered for 4 Weeks to Subjects with Osteoarthritic Pain of the Knee

2005 Principal Investigator: A Double-Blind, Long-Term Evaluation of the Safety of Topically Applied Ketoprofen Transfersome® Gel (KTG) in Comparison to Oral Naproxen for the Treatment of the Signs and Symptoms of Osteoarthritis of the Knee

2005 Principal Investigator: A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Doses of Topically Applied Ketoprofen Transfersome® Gel (KTG) in Comparison to Oral Naproxen for the Treatment of the Signs and Symptoms of Osteoarthritis of the Knee

2005 Sub Investigator: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling

2005 Principal Investigator: A Single Dose, 2-Period Cross-over Design Pilot Pharmacokinetic Study of Tacrolimus 5 mg Capsules in Healthy Subjects

2005 Sub Investigator: The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects with Insomnia Related to Generalized Anxiety Disorder

2005 Principal Investigator: An Open-Label Study Evaluating the Safety and Tolerability of Long Term Administration of Hydrocodone/Acetaminophen Extended Release Tablets (Vicodin® CR) in Subjects with Moderate to Severe Chronic Non-Malignant Pain

2005 Principal Investigator: Efficacy of Axert® (Almotriptan malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy with Topamax® (Topiramate)

2005 Sub Investigator: A randomized, double-blind, placebo-controlled, forced-titration, Phase IV study comparing telmisartan 80 mg + hydrochlorothiazide 25 mg versus valsartan 160 mg + hydrochlorothiazide 25 mg taken orally for eight weeks in patients with Stage l or Stage 2 hypertension

2005 Principal Investigator: A Randomized Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Safety and Efficacy of HKT-500 in Subjects with Low Back Pain

2005 Principal Investigator: A Randomized, Multicenter, Double Blind, Placebo-Controlled, Single Dose Comparison of the Analgesic Activity of HKT-500 and Placebo in Subjects with Shoulder Pain

2005 Principal Investigator: A Randomized, Double-Blind, Daytime, 4-Way Crossover Study to Evaluate the Pharmacokinetics, Dose Proportionality, Pharmacodynamics, Safety, and Tolerability of Three Doses of Sublingual Zolpidem Tartrate Lozenges Compared to Placebo in Normal Healthy Volunteers

2005 Sub-Investigator: An International, Multi-center, Double-blind, Randomized, Parallel-group, Placebo- controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg dose) and Paroxetine as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks and Quetiapine in Continuation Treatment for 26 up to 52 weeks

2005 Sub Investigator: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel- Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects with Idiopathic Restless Legs Syndrome

2005 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of Doxepin HCL in Primary Insomnia Patients with Sleep Maintenance Difficulties

2005 Principal Investigator: A 1-Year Open-Label, Flexible-Dosage Extension Study to Assess the Safety and continued Effectiveness of Provigil (Modafinil Treatment in Children and Adolescents with Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

2005 Principal Investigator: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Provigil (Modafinil) Treatment (100, 200, and 400 mg/day) in Children and Adolescents with Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome

2005 Principal Investigator: A Phase 3, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Provigil (Modafinil) Treatment (100, 200, and 400 mg/day) in Children and Adolescents with Excessive Sleepiness Associated with Narcolepsy

2005 Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects with Premenstrual Dysphoric Disorder

2005 Sub-Investigator: A Phase III, 12-Week, Multicenter, Double-Blind, Randomized, Placebo and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily in Adults with Rheumatoid Arthritis

2005 Sub-Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Primary Insomnia Patients with Sleep Maintenance Difficulties

2005 Principal Investigator: A Phase III, 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Placebo and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5mg, 10mg, 25mg and 50mg administered orally once daily in adults with Osteoarthritis of the knee

2005 Principal Investigator: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

2005 Sub-Investigator: A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel group Trial of Lumiracoxib (COX 189) 100 mg o.d. in Patients with Primary Hip Osteoarthritis Using Celecoxib (200mg o.d.) as a Positive Control

2005 Sub-Investigator: A 20 week multi-national, open-labeled, randomized, three-group parallel trial comparing administration of insulin detemir morning, insulin detemir evening and NPH insulin evening and add-on oral antidiabetic drug(s) in subjects with type 2 diabetes

2004 Principal Investigator: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Adult Patients with Primary Insomnia

2004 Principal Investigator: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Elderly Patients with Primary Insomnia

2004 Principal Investigator: A Randomized, 4-Way Cross-Over, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Trial with Three Dosages of ORG 50081 in Patients with Primary Insomnia

2004 Principal Investigator: A 12-Week, Double-Blind, Placebo-Controlled, Twice Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

2004 Principal Investigator: A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter study of Gabapentin 250 mg and 500 mg in Transient Insomnia Induced by a Sleep Phase Advance

2004 Sub Investigator: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled 5-Way Crossover Study of the Safety and Efficacy of PD-0341806, Zolpidem, and Placebo in Primary Insomnia

2004 Sub Investigator: A Study to Define the Non-Restorative Sleep Population

2004 Principal Investigator: A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs. Placebo on Pulmonary Function and Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease (COPD)

2004 Principal Investigator: Open-Label, Long-term, Multicenter Study of Safety and Tolerability of Valdecoxib 40-60 mg in the Acute Treatment of Migraine in Adults

2004 Principal Investigator: A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima™ in the Acute Treatment of Migraine Headaches

2004 Sub Investigator: BUP 3015 A Multicenter, Randomized, Double-Blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or OxyIR® versus BTDS 5 in Subjects with Moderate to Severe Low Back Pain

2004 Principal Investigator: A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-group Study Comparing the Safety and Efficacy of Hydromorphone HCl Extended-release and Duragesic ® in Subjects with Non-Malignant Pain

2004 Sub Investigator: Evaluation of the Long-Term Efficacy and Safety of Zolpidem-MR 12.5-mg. Compared to Placebo, when both are Administered over a Long-Term Period "as needed", in Patients with Chronic Primary Insomnia. (A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase III Clinical Study)

2004 Principal Investigator: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to assess the Efficacy and Safety of Doxepin in Patients with Primary Sleep Maintenance Insomnia

2004 Sub Investigator: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy and Safety of Doxepin HCI in Elderly Patients with Primary Sleep Maintenance Insomnia.

2004 Sub Investigator: A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of J867 vs. Placebo in Subjects with Uterine Lelomyomata

2004 Principal Investigator: Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment with USL-221 on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Post-Menopausal Patients

2004 Sub Investigator: A Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Gabitril ® (4, 6, 8 and 10 mg) Treatment in Adult Patients with Primary Insomnia

2004 Principal Investigator: A Randomized Double Blind Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Gabitril ® (2, 4, 6 and 8 mg) Treatment in Adult Patients with Primary Insomnia

2004 Sub Investigator: A 12-Week Double-Blind, Parallel-Group, Placebo and Active-Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20mcg in the Treatment of Patients with Chronic Obstructive Pulmonary Disease, Followed by a 40-Week Open-Label Safety Extension

2004 Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Phase 2, Parallel Group, Dose-Range Finding Study to assess the Safety and Efficacy of GW406381 Administered for 42 days to Subjects with Rheumatoid Arthritis

2004 Principal Investigator: A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCI Once-a-Day Versus Placebo for the Treatment of Pain due to Osteoarthritis

2004 Principal Investigator: A Randomized, Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis or Rheumatoid Arthritis

2004 Sub Investigator: Neurocrine Biosciences, Inc. Protocol NBI-34060-MR-0306: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Access the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties

2004 Principal Investigator: A 13-Week, multicenter, randomized, double-blind, double-dummy, placebo controlled, parallel trial of 2 different dose regimens of Lumiracoxib (100mg od and 200mg od initial dose for two weeks followed by 100mg od) in patients with primary knee Osteoarthritis, using Celecoxib (200mg od) as a comparator

2004 Principal Investigator: A 52-Week, international, multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability, and efficacy of Lumiracoxib 100mg od, Lumiracoxib 100 mg bid and Celecoxib 200mg od in patients with primary osteoarthritis of hip, knee, hand, or spine

2004 Principal Investigator: A Four-Week Double Blind, Placebo-Controlled Exploratory Evaluation of FEV 1.0 Changes and Safety of ONO-6126 in Patients with Chronic Obstructive Pulmonary Disease (COPD). Ono Pharma USA

2004 Sub Investigator: Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (sodium oxybase) with Modafinil with Placebo for the Treatment of Daytime Sleepiness in Narcolepsy

2004 Principal Investigator: A Comparison of Topiramate versus Amitriptyline in Migraine Prophylaxis (Phase IIIB)

2004 Principal Investigator: An Open-Label Study of the Safety and Efficacy of Topiramate for Migraine Prophylaxis: Extension Study

2004 Principal Investigator: Axert ® Early Migraine Intervention Study (AEGIS): Efficacy and Safety of Axert ® (Almotriptan Malate) Versus Placebo for the Acute Treatment of Migraine Headache

2004 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of Oral Almotriptan 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents

2004 Principal Investigator: Effect of Alagebrium (ALT-711) in Combination with Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients

2004 Principal Investigator: Protocol #324: A Phase III, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, Parallel Group Factorial Study of Metoprolol Succinate Extended-Release Tablets (Toprol-XL®), Hydrochlorothiazide and Their Combination in Patients with Essential Hypertension

2004 Principal Investigator: A 24-Week Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly Controlled on Insulin

2004 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function with Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)

2004 Sub Investigator: A Phase II Double Blind, Randomized, Dose Ranging, Placebo Controlled, Multi-center, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer's Type

2004 Sub Investigator: A 12-Month, Open-Labeled, Flexible-Dosage (100-250 mg/day) Extension Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

2004 Principal Investigator: A 12-Month Open-Label, Flexible-Dosage (100-250 mg/day) Extension Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder.

2004 Sub Investigator: A 12-month, Open-Labeled Study to Evaluate Safety and Efficacy of Gabitril ® at dosages up to 8 mg/day in Elderly Adults with Primary Insomnia

2004 Principal Investigator: A 26-Week, Randomized, Placebo and Active-Comparator-Controlled, Parallel- Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg vs. Celecoxib 200 mg in Patients with Osteoarthritis (Study I)

2004 Principal Investigator: A 12-week Double-Blind, Parallel-Group, Placebo and Active-Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 mcg in the Treatment of Patients with Chronic Obstructive Pulmonary Disease, Fol1owed by a 40-Week Open-Label Safety Extension

2004 Principal Investigator: Study Title: A 28-Week Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Extended Release Avandamet in Subjects with Type 2 Diabetes Mellitus

2004 Sub Investigator: A multicenter, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of PD 0299685 for the treatment of vasomotor symptoms of menopause in postmenopausal women

2004 Principle Investigator: A randomized, double-blind, placebo-controlled, parallel group clinical trial comparing fixed doses of 0.25 mg, 0.50 mg and 0.75 mg pramipexole (Mirapex®) administered orally to investigate the safety and efficacy in patients with idiopathic Restless Legs Syndrome for 12 weeks

2004 Sub Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Fixed- Dose, Polysomnographic Study of PD 0200390 in Patients with Primary Insomnia

2004 Principal Investigator: An Open-Label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine Over 12 Months

2004 Principal Investigator: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/day) as Treatment for Adults with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome

2004 Sub Investigator: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/day) as Treatment for Adults with Excessive Sleepiness Associated with Narcolepsy

2004 Principal Investigator: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 mg) as Treatment for Adults with Excessive Sleepiness Associated with Chronic Shift Work Sleep Disorder

2004 Sub Investigator: A 12-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 mg/day) as Treatment for Adults with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome

2004 Principal Investigator: A Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of GABITRIL® (4, 6, 8, and 10 mg) Treatment in Adult Patients with Primary Insomnia

2004 Principal Investigator: A 12Month, Open-Label Study to Evaluate Safety and Efficacy of Gabatril® at Dosages up to 10 mg/day in Adult Patients with Primary Insomnia

2004 Principal Investigator: A Randomized, Double Blind, Placebo-Controlled, Paral1el-Group Study of the Efficacy and Safety of Gabatril® (2, 4, 6, and 8 mg) Treatment in Elderly Patients with Primary Insomnia

2004 Principal Investigator: A 12-Month, Open-Label Study to Evaluate Safety and Efficacy of Gabatril® at Dosages up to 8 mg/day in Elderly Adults with Primary Insomnia

2004 Principal Investigator: A 39-Week, Open-Label Extension to CCOX189A2360, a 13-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od) in Patients with Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator

2004 Principal Investigator: Comparison of Pharmacokinetics and Pharmacodynamics Following Single Dose Administration of Furosemide GR™ Tablets, 40 mg and Furosemide Immediate Release Tablets, 40 mg in Patients with Congestive Heart Failure

2004 Sub Investigator: A Multicenter, Randomized, Parallel-Group, and Double-Blind, Phase III comparison of the Efficacy and Safety of Quetiapine Fumarate (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

2004 Sub Investigator: A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (oral tablets 400 mg to 800 mg daily m divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

2004 Sub Investigator: Depression Response to Eszopiclone in Adults with Major Depressive Disorder (DREAMDD): A Randomized, Double Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety and Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects with Insomnia Related to Major Depressive Disorder

2004 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release (3900 mg/day) in the Treatment of Osteoarthritis of the Hip or Knee

2004 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties

2003 Principal Investigator: A Six Month, Chronic Efficacy and Safety Study of Eszopiclone in Adult Subjects with Primary Insomnia: A Randomized Double-Blind, Placebo-Controlled Study

2003 Principal Investigator: A Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine

2003 Principal Investigator: A 13-Week, Mu1ticenter, Randomized, Double-Blind, Double-Dummy, Placebo- Controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od) in Patients with Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator

2003 Principal Investigator: A Four-Week, Double-Blind, Placebo-Controlled Exploratory Evaluation of FEV 1.0 Changes and Safety of ONO-6126 in Patients with Chronic Obstructive Pulmonary Disease (COPD)

2003 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 for the Treatment of Transient Insomnia in Adult Subjects

2003 Principal Investigator: A Phase II Safety Study of TAK-375 in Subjects with Mild to Moderate Chronic Obstructive Pulmonary Disease

2003 Sub Investigator: A 7-Month, Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase

2003 Principal Investigator: A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)

2003 Sub Investigator: Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (sodium oxybate) with Modafinil with Placebo for the Treatment of Daytime Sleepiness in Narcolepsy

2003 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of NBI-34060 in Adult Patients with Primary Insomnia

2003 Sub Investigator: Multicenter, Three-Arm, Partially Double-Blinded, Placebo-Controlled Outpatient Comparison of Efficacy and Safety of Buffered 4% Miconazole Nitrate (200 mg) Vaginal Cream Compared with Metro-Gel Vaginal for the Treatment of Bacterial Vaginosis (BV)

2003 Principal Investigator: A Double-Blind, Randomized, Controlled, Parallel-Group, Multicenter Study Evaluating the Safety and Efficacy of Civamide Cream 0.075% as a Treatment in Subjects with Osteoarthritis of the Knee

2003 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of Oral Almotriptan 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents

2003 Principal Investigator: Topiramate versus Amitriptyline HCI versus Placebo in Migraine Prophylaxis: A Comparison of Efficacy, Safety, Impact on Weight and Quality of Life

2003 Principal Investigator: A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Safety and Efficacy of Hydromorphone HCl Extended-Release and Duragesic® in Subjects with Non-Malignant Pain

2003 Principal Investigator: A Phase III, Multi-Center, Randomized, Double Blind, Placebo-Controlled Parallel Group Factorial Study of Metoprolol Succinate Extended-Release Tablets (Toprol-XL®), Hydrochlorothiazide and Their Combination in Patients with Essential Hypertension

2003 Principal Investigator: A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs. Placebo on Pulmonary Function and Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease (COPD)

2003 Sub Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia

2003 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety and Efficacy of TAK-375 in Elderly Subjects with Chronic Insomnia

2003 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, PSG plus Outpatient Study to Determine the Safety and Efficacy of TAK-375 in Adults with Chronic Insomnia

2003 Principal Investigator: A Randomized, Latin-Square, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabitril (4, 8, 12, and 16 mg) in Patients with Primary Insomnia

2003 Principal Investigator: A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study of the Efficacy and Safety of M100907 Tablets in the Treatment of Sleep Maintenance Insomnia

2003 Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-week Study to Evaluate the Efficacy and Safety of Ezetimibe 10-mg/day When Added to Ongoing Therapy with a Statin Versus Statin Therapy Alone, in Patients with Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level MK-0653

2003 Principal Investigator: A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients with Osteoarthritis

2003 Principal Investigator: A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain due to Osteoarthritis of the Knee

2003 Principal Investigator: A Randomized, Double Blind, Placebo-Controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function with Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)

2002 Principal Investigator: Open-Label, Long-tern, Multicenter Study of Safety and Tolerability of Valdecoxib 40-60 mg in the Acute Treatment of Migraine in Adults

2002 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties

2002 Principal Investigator: Clinical Protocol for a 12 Week, Randomized, Double-Blind, Placebo Controlled Multicenter Study of the Analgesic Efficacy of Celecoxib 200 mg QD, Compared to Placebo in Patients with Chronic Low Back Pain

2002 Sub-Investigator: A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of J867 versus Placebo in Subjects with Uterine Leiomyomata

2002 Principal Investigator: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS)

2002 Principal Investigator: A Phase III, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral TMX-67 versus Allopurinol in Subjects with Gout

2002 Principal Investigator: An Open-Label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers who are Dissatisfied with Rizatriptan Therapy

2002 Principal Investigator: Clinical Utility of Amlodipine/Atorvastatin to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia

2002 Principal Investigator: A Double-Blind, Multi-Center, Randomized. Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients with Mild to Moderate Hypertension

2002 Sub Investigator: Acute Effects on Sleep Latency in Patients with Moderate Sleep Disturbances II

2002 Sub Investigator: A Randomized, Double-Blind, Active-and-Placebo-Controlled 4-Way Crossover Study of the Safety and Efficacy of PD0200390, Zolpidem, and Placebo in Primary Insomnia

2002 Sub Investigator: A Double-Blind, Randomized, Placebo and Active Controlled Crossover Study of PD0200390 in a 4-Hour Phase Advanced Model of Transient Insomnia in Healthy Volunteers

2002 Sub Investigator: A 30-Day Multi-Center, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ANPH 101 for Sleep Maintenance in Adult Patients with Chronic Primary Insomnia

2002 Principal Investigator: An Open Label Study Assessing Paxil CR in Subjects with Major Depressive Disorder Who Discontinued Treatment with Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/Norepinephrine Reuptake Inhibitor due to Intolerability

2002 Sub Investigator: A Double-Blind, Multicenter, Placebo-Controlled Study of L-830982 Gel Extrusion Module (GEM) 1.5mg bid to 4.5mg bid Versus Lorazepam in the Treatment of Outpatients with Generalized Anxiety Disorder

2002 Sub Investigator: A 6 ½ Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder

2002 Sub Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 8 Weeks of Oral Provigil (Modafinil) Tablets {CIV} (200mg Once Daily) as Adjunctive Treatment for Excessive Sleepiness in Adults with Major Depressive Disorder, Sleepiness and Fatigue, followed by a 12 Week Open Label Period

2002 Sub Investigator: A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer's Type

2002 Principal Investigator: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group study comparing the Efficacy and Safety of Zolpidem-MR 12.5mg and placebo in patients with Primary Insomnia

2002 Principal Investigator: A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Access the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Leg Syndrome Suffering from Periodic Leg Movements of Sleep

2002 Principal Investigator: A Phase III, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of NBI-34060 Adults with Primary Insomnia

2002 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of NBI-34060 for the Treatment of Transient Insomnia in Adult Subjects

2002 Principal Investigator: A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis or Rheumatoid Arthritis

2002 Investigator: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study Evaluating Efficacy and Safety of Three Doses of SB-659746-A (5mg, 10mg, and 20mg) Versus Placebo in Patients with Major Depressive Disorder

2002 Sub Investigator: Deramciclane 30 mg and 60mg Once Daily in Generalized Anxiety Disorder. A Randomized Double-Blind Placebo and Buspirone-Controlled Fixed-Dose Parallel-Group Multicenter Study of 10 Weeks Including A 2 Week Single-Blind Placebo Period

2002 Principal Investigator: A Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel Group 6- week Treatment Study Comparing Telmisartan combined with Hydrochlorothiazide (40 mg/12.5 mg or 80 mg/12.5 mg) Tablets with Losartan Combined with Hydrochlorothiazide (50 mg/12.5) Tablets using Ambulatory Blood Pressure Monitoring in Patients with Mild-to-Moderate Hypertension

2002 Principal Investigator: A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Clinical Trial of Anti-CD4 Receptor Human Moloclonal Antibody (HuMax-CD4) in combination with Methotrexate in Patients with Active Rheumatoid Arthritis

2002 Principal Investigator: A Double-Blind, Randomized, Active and Placebo Controlled, Parallel Group, Single and Multiple Dose Assessment of the Analgesic Efficacy of Celecoxib Formulation B in the treatment of Patients with Primary Dysmenorrhea

2002 Sub Investigator: Deramciclane 60 mg (or 39 mg) Once Daily in the treatment of Generalized Anxiety Disorder. An Open, Multicenter Safety Study of 5 months, including a 1 Month Drug-Free Follow-Up Period

2002 Principal Investigator: A randomized, double-blind, placebo controlled evaluation of the safety and efficacy of xxx in the acute treatment of migraine

2002 Principal Investigator; A multinational, multi-center, randomized, double-blind, parallel group, active controlled, comparative trial to assess the endometrial histological profile following treatment with xxx vs. xxx in postmenopausal women

2002 Principal Investigator: Clinical protocol for a randomized, double-blind, active and placebo controlled; parallel group, single and multiple dose assessment of the analgesic efficacy of xxx in the treatment of patients with Primary Dysmenorrhea

2002 Principal Investigator: Phase III, open-label, multicenter, multinational, contraceptive Study of xxx and xxx injectable suspension administered subcutaneously

2002 Principal Investigator: A double-blind, randomized, placebo-controlled multicenter study to investigate the long-term safety of 2 mg PRN of xxx in diarrhea-predominant irritable bowel syndrome subjects

2002 Principal Investigator: An international, multi center, stratified, randomized, double-blind, double- dummy, parallel-group, 52-week gastrointestinal clinical safety study to demonstrate that xxx reduces the risk to develop complicated ulcers as compared to xxx in osteoarthritis patients

2002 Principal Investigator: Safety and Pharmacokinetic Variability and Exposure to a Single Dose and Multiple Daily Doses of (R)-Didesmethylsibutramine in Healthy Subjects

2002 Principal Investigator: A Randomized, Double-Blind, Placebo Controlled. Parallel- Group Study to Evaluate the Efficacy and Safety of 12 weeks of Provigil (Modafinil) Therapy at a Dose of 200 mg as Treatment for Adults with Excessive Sleepiness Associated with Chronic Shift Work Sleep Disorder, Followed by a 12 Month Open-Label Extension Period. Protocol C1538a/305/CM/US-UK

2001 Principal Investigator: A Randomized, Double Blind, Placebo-Controlled, Dose-Response Study to
Assess the Efficacy and Safety of Modified Release Formulation of NBJ-34060-MR-0103.

2001 Principal Investigator: A Randomized, Double Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy and Safety of Modified Release Formulation of NBI-34060-MR-0102

2001 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy and Safety of NBI-34060 in patients with Chronic Insomnia

2001 Principal Investigator: A Double-Blind Placebo-Controlled, Parallel Group Design Study of Two Doses of Lasofoxifene vs. Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women

2001 Principal Investigator: A Double-Blind Placebo-Controlled, Parallel Group Design Study of Two Doses of Lasofoxifine vs. Placebo for the Treatment of Sexual Dysfunction (Hypoactive Desire) in Postmenopausal Women

2001 Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo Controlled Study of Eletriptan (20 and 40 mg) Versus Placebo in Early Treatment of Migraine

2001 Principal Investigator: A Phase II, 12 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy of Three Fixed Doses of Oral CP-457,920 (30 mg QD, 60 mg BID and 120 mg BID) and Donepezil in Outpatients with Alzheimer's Disease

2001 Principal Investigator: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MT 100 for the Treatment of Migraine in Subjects who are Intolerant to 5-HT Agonists or have Cardiovascular Risk Factors

2001 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of MT 500 in Patients with Migraine

2001 Principal Investigator: A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study of (R, R)-Formoterol in the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)

2001 Principal Investigator: A Placebo-Controlled Dose-Titration Efficacy and Tolerability Study of Neotrofin in Patients with Probable Alzheimer's Disease

2001 Principal Investigator: A Randomized Double Blind, Placebo-Controlled Parallel Study of the Efficacy and Safety of (S)- Zipiclone in the Treatment of Adult Subjects with Primary Insomnia

2001 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Parallel, Two-Week Objective Efficacy and Safety Study of Esopiclone in Elderly Subjects with Primary Insomnia

2001 Principal Investigator: An Efficacy, Safety and Dose Response Study of TAK-375 in Subjects with Chronic Insomnia

2001 Principal Investigator: A Double-Blind, Placebo-Controlled, Two-Attack Cross-Over Study to Assess the Efficacy of Frovatriptan 2.5 mg Taken for Mild Migraine Headache

2001 Principal Investigator: A Double Blind, Placebo-Controlled, Cross-Over Study of Next-Day Performance Effect of (S)- Zopiclone in Healthy Subjects

2001 Principal Investigator: A Double-Blind, Placebo-Controlled, Cross-Over Study of Next-Day Performance Effect of (S)-Zopiclone in Subjects with Insomnia

2001 Principal Investigator: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study Evaluating Efficacy and Safety of Three Doses of SB-659746-A (5mg, 10mg, and 20mg) Versus Placebo in Patients with Major Depressive Disorder

2001 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Impact on Quality of Life of 12 Weeks of Provigil (Modafinil) Therapy at Dosages of 200 and 300 mg Once Daily as Treatment for Adults with Excessive Sleepiness Associated With Shift Work Sleep Disorder, Followed by a 12-Month Open-Label Extension Period

2001 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of DVD742 in the Treatment of Non-Demented Older Individuals with Mild Cognitive Impairment

2001 Principal Investigator: Phase II, 12 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 (3Omg QD,60 mg BID and 120mg BID) and Donepezil in Outpatients with Alzheimer's Disease

2000 Principal Investigator: A Phase I Double-Blind, Placebo and Active Comparator Controlled, Cross-Over Evaluation of the Hypnotic Activity of CP-374,031

2000 Principal Investigator: A Randomized, Double-blind, Long-Term Comparative Study Evaluating the Safety and Efficacy of Acetaminophen (4000 mg/day) and Drug in the Treatment of Osteoarthritis of the Hip and Knee

2000 Principal Investigator: Medroxyprogesterone Acetate (MPA)/Estradiol Cypionate (E2C) Injectable Suspension; A Study of Bleeding Pattern in Pre-Menopausal Women after Subcutaneous Administration of 20 mg MPA in Combination with Either 2.5 mg, 5.0mg, 7.5 mg, or 10.0 mg E2C

2000 Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Comparative Study of the Efficacy and Safety of Oral Eletriptan (40 mg) and Sumatriptan (100 mg) Given for the Acute Treatment of Migraine

2000 Principal Investigator: An Open-Label Extension to Assess the Safety and Efficacy of Once Daily Dosing of 150mg AIT-082 Administered over 52 Weeks in Patients with Probable Alzheimer's Who are Currently or were Previously Enrolled in the Double-Blind Portion of Protocol XXXX

2000 Principal Investigator: Reboxetine, Placebo, and Paroxetine Comparison in Patients with Major Depressive Disorder

2000 Principal Investigator: An Open-Label Reboxetine Continuation Therapy

2000 Principal Investigator: Pharmacogenomics Blood Sampling Protocol

2000 Principal Investigator: Reboxetine, Placebo, and Paroxetine Comparison in Patients with Major Depressive Disorder

2000 Principal Investigator: Evaluation of Solvent/Detergent Treated Plasma, Isoaglutin Depleted in Normal Healthy Volunteers

2000 Principal Investigator: A Randomized, Double Blind, Placebo-Controlled, Single-Dose, First Night Effect Sleep Laboratory Study of Two Doses of TAK-375 in Healthy Adult Volunteers

2000 Principal Investigator: Prospective, randomized, double-blind study comparing Faropenem Daloxate 300 mg PO BID for 5 days with trimethoprim/ sulfamethoxazole 160/800 mg PO BID for 5 days in the treatment of patients with acute, uncomplicated lower urinary tract infections

2000 Principal Investigator: Prospective, randomized, double-blind study comparing Faropenem Daloxate 300 mg PO BID for 5 days with Azithromycin for 5 days (500 mg PO day 1, then 250 mg PO OD days 2-5) in the treatment of patients with acute exacerbation of chronic bronchitis

2000 Principal Investigator: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID and 440mcg BID

versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteriod Therapy

2000 Principal Investigator: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of inhaled Fluticasone Propionate 88mcg BID, 220mcg BID and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy

2000 Principal Investigator: An Open-Label Study to Investigate the Effect of Migraine Attacks on the Pharmacokinetics of a Single Dose of MT 100 (metoclopramide hydrochloride and naproxen sodium) administered both during and Outside of Migraine Attacks

2000 Principal Investigator: A 24 Week Randomized, Open Label Study of Health Care Resource Use, Quality of Life and Productivity with Alosetron 1 mg Twice Daily Versus Traditional Therapy in Females with Irritable Bowel Syndrome whose Predominant Bowel Symptom is Diarrhea

2000 Principal Investigator: Reboxetine, placebo, and paroxetine comparison in patients with Major Depressive Disorder

2000 Principal Investigator: A Double-Blind, Placebo-Controlled Parallel Randomized Six-Way Crossover Study of the Efficacy and Safety of (S)-Zopiclone in the Treatment of Adult Patients with Primary Insomnia

2000 Principal Investigator: A Dose-Ranging, Double Blind, Placebo-Controlled, Safety, Tolerability, and Efficacy Study of (R) -Didesmethyl Sibutramine in Patients with Major Depressive Disorder by DSM-IV Criteria

2000 Principal Investigator: An Efficacy, Safety and Tolerability Study of (S) - Zopiclone in Subjects with Transient Insomnia (First Night Effect Model)

2000 Principal Investigator: An Open Label Study of Eletriptan (40 MG) for the Acute Treatment of Migraine in Migraine Sufferers who are Dissatisfied with Excedrin Migraine® Treatment

2000 Principal Investigator: Phase I, Double-Blind, Placebo and Active Comparator Controlled Cross-over Evaluation of the Hypnotic Activity of CP-374,031

2000 Principal Investigator: A randomized, double-blind, placebo-controlled, dose-response study to assess the efficacy and safety of NBI-34060 in patients with chronic insomnia

2000 Principal Investigator: A Placebo-Controlled, Double-Blind, Randomized Trial of a Tablet Formulation of Pleconaril in the Treatment of Viral Respiratory Infection in Adults

2000 Principal Investigator: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of 12 Weeks of 2 Oral Doses (200 mg and 400 mg Once Daily) Of PROVIGIL ® (Modafinil) As Treatment for Adults

with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome Followed By A 9-Month Open-Label Extension

2000 Principal Investigator: A Randomized, Double-Blind, Long-Term Comparative Study Evaluating the Safety and Efficacy of Acetaminophen (4000 mg/day) and Naproxen (750 mg/day) in the Treatment of Osteoarthritis of the Hip or Knee

2000 Principal Investigator: A Randomized, Double-Blind, Parallel, Multicenter, Placebo-Controlled, Two Year Study to Determine the Efficacy and Safety of Orally Administered 5 and 15mg/day, and 50 mg/week Risedronate in Patients with Medical Compartment Osteoarthritis in North America

2000 Principal Investigator: A Randomized, Double Blind, Multicenter, Comparative Phase III Study of Oral BMS-284756 vs. Oral Azithromycin in the Treatment of Acute Exacerbation of Chronic Bronchitis

2000 Principal Investigator: Double-Blind, Placebo-Controlled Study of Venlafaxine ER in Children and Adolescents with Generalized Anxiety Disorder

2000 Principal Investigator: Omapatrilat Cardiovascular Treatment Assessment versus Enalapril

2000 Principal Investigator: A Double-Blind Randomized Study to Evaluate the Effects of Fixed Combination Metformin/Glipizide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Half-Maximum to Maximum of the Labeled Doses of Sulfonylurea Monotherapy

2000 Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo Controlled Parallel Group Comparative Study of the Efficacy and Safety of Oral Eletriptan (40 mg) and Sumatriptan (100 MG) Given for the Acute Treatment of Migraine

2000 Principal Investigator: A Multicenter, Randomized, Placebo- and Active-Controlled, Five-Way, Crossover Study of (R, R) -Formoterol Tartrate Inhalation Solution and Salmeterol in Subjects with Chronic Obstructive Pulmonary Disease

1999 Principal Investigator: A Double-Blind, Placebo-Controlled, Multi-Center, Randomized, Parallel-Group Study of the Effect of Four-Weeks of Provigil (Modafinil) Treatment on Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients Treated with Nasal Continuous Positive Airway Pressure Followed by a Twelve -Week Open-Label Extension

1999 Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AIT-082 in Patients with Probable Alzheimer's Disease of Mild to Moderate Severity (90 day treatment period plus 60 day follow-up)

1999 Principal Investigator: A Randomized, Double Blind, Placebo-Controlled, Phase III Trial Evaluating Zoledronate Plus Standard Therapy vs. Placebo + Standard Therapy in Patients

with Recurrent Carcinoma of Prostate Who are Asymptomatic with Castrate Levels of Testosterone and have Rising PSA Levels without Radiological Evident Metastatic Disease

1999 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Tegaserod 12 mg/d and Placebo in Females with Constipation-Predominant Irritable Bowel Syndrome (C-IBS)

1999 Sub Investigator: A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Phase II Study to Assess the Clinical Efficacy of Alosetron in Male Subjects with Irritable Bowel Syndrome

1999 Sub Investigator: A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled Study of Alosetron in Female Subjects with Alternating Diarrhea/Constipation Irritable Bowel Syndrome

1999 Principal Investigator: A Comparison of the Analgesic Efficacy and Safety of Tramadol HCL/Acetaminophen versus Placebo for the Treatment of a Painful Flare of Osteoarthritis

1999 Principal Investigator: A Randomized, Double-Blind, Parallel, Multicenter, Placebo-Controlled, Two Year Study to Determine the Efficacy and Safety of Orally Administered 5 and 15 mg/day, and 50 mg/week Risedronate in Patients with Medial Compartment Knee Osteoarthritis in North America

1999 Principal Investigator: A Single Dose, Double-Blind, Safety and Efficacy Study of MT 100, Metoclopramide Hydrochloride and Naproxen Sodium in Subjects with Acute Migraine Attacks

1999 Principal Investigator: An Open-Label, Repeat Dose, Long-Term Safety Study of MT 100 in Subjects with Acute Migraine Attacks

1999 Principal Investigator: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Tolerability and Effectiveness of Rofecoxib 25mg QD vs. Naproxen 500 mg BID in Patients with Osteoarthritis

1999 Principal Investigator: A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy and Safety of Celecoxib 100 mg BID, and Diclofenac 50 mg TID in Treating the Signs and Symptoms of Osteoarthritis of the Knee

1999 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Given Orally at Three Dose Levels (0.4 mg, 1mg or 4 mg daily) and Placebo in Patients with Non-Erosive Gastro-Esophageal, Reflux Disease (GERD)

1999 Sub Investigator: A Randomized, Double Blind, Placebo-Controlled Study of L-759274 vs. Paroxetine Hydrochloride in Outpatients with Major Depressive Disorder

1999 Sub Investigator: A Double-Blind, Randomized Comparison of PNU-101017E, Lorazepam, and Placebo in Generalized Anxiety Disorder

1999 Principal Investigator: Oral Study Drug vs. Oral Sumatriptan in a Double-Blind, Randomized, Parallel Group Study of Cost-Effectiveness and Quality of Life in Migraine

1999 Sub Investigator: R-Fluoxetine versus Placebo in the Treatment of Major Depression Disorder

1999 Sub Investigator: A Double-Blind, Placebo and Fluoxetine Controlled, Multicenter Study Evaluating the Efficacy and Safety of SR4896C with Major Depressive Disorder

1999 Principal Investigator: A Six-Week, Open-Label Study of Safety and Efficacy of Study Drug in Patients Switching from Stimulant Therapy for Narcolepsy-Associated Excessive Daytime Sleepiness, followed by a Six-Month Open-Label Extension

1999 Principal Investigator: A Phase II, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of Study Drug 2.5mg TID, 5mg TID, and 7.5mg TID and 10mg TID for a Period of 16 Weeks in Patients with a Diagnosis of Chronic Fatigue Syndrome

1999 Principal Investigator: A Single Dose, Placebo-Controlled, Multicenter, Dose Ranging Trial of Study Drug in Patients with Acute Migraine Headaches

1999 Principal Investigator: A Long-Term, Open-Label Safety Study of Study Drug 12.5mg Orally in Migraine Patients

1999 Sub Investigator: A Randomized, Double-Blind, Placebo-Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40 mg/day Paroxetine in Patients with Generalized Anxiety Disorder

1999 Sub Investigator: Fluoxetine versus Placebo in Posttraumatic Stress Disorder

1998 Sub Investigator: A Double-Blind, Five-Armed, Fixed Dose, Active-and Placebo-Controlled Dose-Finding Study with Sublingual ORG 5222 in Subjects with Acute Phase Schizophrenia

1998 Principal Investigator: Long-Term Efficacy, Safety, and Health Care Outcomes in Patients Receiving Open-Label Lazbemide Therapy

1998 Principal Investigator: A Randomized, Double-Blind, Active-And Placebo-Controlled, Parallel Group, Dose Response Study of the Safety, Pharmacokinetics and Effect on Pain and Function of Study Drug in Subjects with Osteoarthritis of the Knee

1998 Principal Investigator: A Randomized, Double-Blind, Active-And Placebo-Controlled, Parallel Group, Dose Response Study of the Anti-Inflammatory Activity, Safety and Pharmacokinetics of Study Drug in Subjects with Rheumatoid Arthritis

1998 Principal Investigator: A Multicenter, Randomized, Double Blind, and Comparative Study of Oral Study Drug versus Oral Drug for Out Patient Treatment of Acute Exacerbation of Chronic Bronchitis in Adults

1998 Principal Investigator: A Double Blind, Multicenter, Randomized, Active Two-Arm Parallel-Group Comparative Study of Efficacy and Safety of Oral Study Drug versus Oral Drug in the Treatment of Community-Acquired Pneumonia in Adults

1998 Principal Investigator: A Multicenter, Randomized, Double Blind, Three-Period Crossover Study to Evaluate Residual Sedation Following the Administration of Study Drug, Drug, and Placebo after a Nocturnal Awakening in Patients with Sleep Maintenance Insomnia

1998 Principal Investigator: Comparative Safety and Efficacy of Study Drug and Drug in the Treatment of
Patients with Acute Maxillary Sinusitis

1998 Sub Investigator: MK-0966 for the Treatment of Mild Cognitive Impairment and Prevention of Conversion to Alzheimer's Disease

1998 Sub Investigator: An Open-Label Comparison of the Neurocognitive Effects of Aripiprazole to Olanzapine Administered Orally in Patients with Stable Psychosis

1998 Principal Investigator: A Double-Blind Randomized Trial Comparing Four Doses of an Intramuscular Formulation of Study Drug and Placebo in the Treatment of Outpatients with Migraine Headache

1998 Principal Investigator: Clinical Protocol for a Multicenter, Randomized, Double-Blind, Parallel Group, Single Oral Dose Comparison Study of Study Drug, Drug and Placebo in Patients with Moderate or Severe Acute Migraine Headache

1998 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Cardiovascular Safety of Study Drug in Patients with Known and at High Risk of Coronary Artery Disease Treating an Acute Attack of Migraine

1998 Principal Investigator: A Randomized, Double Blind, Multicenter, and Comparative Phase III Study of Study Drug versus Drug in the Treatment of Community-Acquired Pneumonia Requiring Hospitalization

1998 Principal Investigator: An Eight-Week, Double-Blind, Placebo-Controlled Study of 2, 20, 50, and 100 mg Study Drug B.I.D. and Drug q.d. in Patients with Major Depressive Disorder

1998 Sub Investigator: The Safety and Efficacy of Long-Term Administration of Extended Release Oral Physostigmine in Alzheimer's disease and Senile Dementia of the Alzheimer Type

1998 Principal Investigator: A Multicenter, Randomized, Double-Blind, Three Period Crossover Study to Evaluate Residual Sedation Following the Administration of 10 mg Study Drug, 10

mg Zolpidem, and Placebo after Nocturnal Awakening in Patients with Sleep Maintenance Insomnia

1998 Sub Investigator: Weekly Enteric Coated Fluoxetine Hydrochloride versus Daily Fluoxetine or Placebo in the Continuation Treatment of Major Depressive Disorder

1998 Sub Investigator: Clinical Protocol to Evaluate the Long-Term Safety of Study Drug in Treating the Signs and Symptoms of Osteoarthritis and Rheumatoid Arthritis

1998 Principal Investigator: The Efficacy, Safety and Tolerability of Study Drug versus Placebo, Administered for One Year in Patients with Probable Alzheimer's Disease

1998 Principal Investigator: A Randomized, Double Blind, Multicenter, Phase II/Ill Comparison of Two Dose Regimens of Study Drug to Drug in the Treatment of Women with Acute, Uncomplicated Urinary Tract Infection

1998 Principal Investigator: A Randomized, Placebo-Controlled, Parallel-Group Study of Study Drug with Long-Term Safety Evaluation in Patients with Essential Hypertension

1998 Sub Investigator: Clinical Protocol for a Multicenter, Double-Blind, Parallel Group Study Comparing the Incidence of Gastro-duodenal Ulcer Associated with Study Drug BID with that of Drug BID taken for 12 weeks in Patients with Osteoarthritis or Rheumatoid Arthritis

1998 Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Study Medication in Adolescent 12 to 17 with Acute Migraine

1997 Sub Investigator: Double-Blind, Placebo-Controlled Study of Drug and Drug in Inpatients with Major Depression and Melancholia

1997 Principal Investigator: Phase III Study of the Efficacy of Drug 1200 mg BID, Controlled-Release (CR), and 600 mg QID, Immediate Release (IR), and Placebo in Patients with Moderate Asthma

1997 Principal Investigator: Double-Blind, Parallel Group, Two-Arm, Active-Control Investigation of Cardiovascular Endpoints

1997 Sub Investigator: Multicenter, Open-Label, Randomized, Two-Arm, Phase II Trial of Drug (2.5 mg po q.d.) Versus the Combination of Drug (2.5 mg po q.d.) + Drug (20.0 mg po q.d.) as First-Line Therapy in Post-Menopausal Women with Advanced Breast Cancer

1997 Sub Investigator: An Active Comparator-Controlled, Parallel-Group, 1-Year, Double-Blind Study, Conducted Under In-House Blinding Conditions, to Assess the Safety and Efficacy of Drug Versus Diclofenac Sodium in Patients with Osteoarthritis of the Knee or Hip

1996 Principal Investigator: A Multicenter, Randomized, Open Label, Comparative Study of the Safety, Toleration, and Efficacy of Drug for Long Term Treatment of Subjects with Acute Migraine

1996 Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Study of the Efficacy and Safety of Oral Drug in Subjects with Acute Migraine

1996 Principal Investigator: A Survey of Narcolepsy Patients on Ritalin Treatment

1996 Principal Investigator: A Phase III, Multicenter, Long-Term, Open-Label Safety and Tolerance Study of 10 or 20 MG of Drug Administered Once Daily for A Maximum of 360 Days in Adult Outpatients with Insomnia

1995 Principal Investigator: A Nine-Week Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Safety and Efficacy of Two Fixed Doses of Oral Drug in Patients with Narcolepsy, followed by a 2 Week Discontinuation Segment, followed by a 40 Week, Open-Label, Flexible-Fixed Dose Continuation Study

1995 Principal Investigator: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety, Tolerance, and Efficacy Study of 2 Doses of Study Drug in Outpatients with Insomnia

1995 Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Factorial Design Dose- Response Study of Drug Alone or in Combination in Patients with Mild to Moderate Essential Hypertension